SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Venus Remedies surges on bagging marketing approval for ‘Elores’ in Myanmar

28 Feb 2014 Evaluate

Venus Remedies is currently trading at Rs. 239.00, up by 9.95 points or 4.34% from its previous closing of Rs. 229.05 on the BSE.

The scrip opened at Rs. 234.90 and has touched a high and low of Rs. 245.20 and Rs. 232.15 respectively. So far 17717 shares were traded on the counter.

The BSE group 'B' stock of face value Rs. 10 has touched a 52 week high of Rs. 358.05 on 15-May-2013 and a 52 week low of Rs. 140.00 on 02-Aug-2013.

Last one week high and low of the scrip stood at Rs. 235.80 and Rs. 217.00 respectively. The current market cap of the company is Rs. 271.92 crore.

The promoters holding in the company stood at 43.99% while Institutions and Non-Institutions held 8.60% and 47.41% respectively.

Venus Remedies, a research-based global pharmaceutical company, is all set to storm into South-east Asia with marketing authorization for its flagship research product, Elores, from Myanmar. The company plans to launch the drug in Myanmar by April.

The company has already received patents for Elores from 46 countries. The registration procedure of this product is in advanced stages in 13 European Union member-nations and 15 other countries, including South Korea, South Africa and Saudi Arabia. The company has signed deals with South Korean pharmaceutical company Goodwill Pharma and South African firm Austell Laboratories for the exclusive marketing of Elores.

Elores has been receiving a tremendous response from the medical fraternity across the country ever since it was launched in India in January 2013. The size of Myanmar’s pharmaceutical market is $400 million and the country imports 85-90 percent of its pharma products. It is looking to capture a sizeable chunk of the antibiotics market in Myanmar.

Venus Remedies Share Price

1042.35 3.25 (0.31%)
17-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1675.20
Dr. Reddys Lab 1235.40
Cipla 1238.30
Zydus Lifesciences 942.55
Lupin 2324.25
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×